Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
Clinical trial NCT01508312 · COMPLETED
Trial details
- NCT number
- NCT01508312
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-01-05
- Primary completion
- 2024-03-14
- Enrollment
- 66
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.